Now in effect: Preferred products for long- and short-acting colony-stimulating factors

April 1, 2021

​Independence is constantly evaluating our policies and industry trends to identify opportunities to make specialty drugs more affordable without limiting members' access to life-saving medications. As a result, Independence has changed how we manage the colony-stimulating factors (CSFs) drug class.

As of April 1, 2021, Independence designated the following CSF drugs as preferred products:

  • Long-acting CSFs
    • Fulphila® (pegfilgrastim-jmdb)
    • Neulasta® (pegfilgrastim)
    • Udenyca® (pegfilgrastim-cbqv)
  • Short-acting CSFs
    • Granix® (tbo-filgrastim)
    • Zarxio® (filgrastim-sndz)

To learn more about these changes and policy updates, please read our announcement article.